Marine Compound Discovery Shows Promise of Improved Drug Treatment for COPD Patients

Published Online: Thursday, January 16, 2014
Follow Pharmacy_Times:
University of Florida pharmacy researchers have isolated a compound from blue-green algae that may inhibit the progression of pulmonary disease.

Related Articles
Everyday walking is the most commonly reported problematic daily activity for patients with chronic obstructive pulmonary disease (COPD).
Warfarin remains a cornerstone anticoagulant for a number of reasons that include its low cost at the pharmacy counter.
High hospital readmission rates plague the health care system.
Carmela Avena-Woods, BSPharm, PharmD, CGP, assistant clinical professor of clinical pharmacy practice in the College of Pharmacy and Health Sciences at St. John's University, talks about the importance of individualizing treatment for COPD.
Latest Issues
$auto_registration$